Pfizer Independent Medical Education Grant Request for Proposals: New Mechanisms and Emerging Treatment Options in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Pfizer Inc. funds independent education projects to advance knowledge of new mechanisms and emerging treatments for metastatic castration resistant prostate cancer (mCRPC).
Funder: Pfizer Inc.
Due Dates: October 21, 2026 (Submission Deadline)
Funding Amounts: $75,000–$250,000 per project | Max duration: 18–24 months | Total program budget: $750,000
Summary: Supports independent medical education projects advancing knowledge of new mechanisms and emerging treatments in metastatic castration resistant prostate cancer (mCRPC).
Key Information: Organizations only (not individuals); U.S. and Europe prioritized, global projects considered.
Description
This grant from Pfizer Inc. funds independent medical education projects focused on new mechanisms and emerging treatment options in metastatic castration resistant prostate cancer (mCRPC). The initiative aims to increase healthcare professionals’ understanding of differentiated mechanisms of action—such as EZH2 inhibition, novel disease mechanisms, and investigational synergies between EZH2 and AR inhibition. The program supports a wide range of educational formats, including live conference sessions, digital content, webinars, and more, all designed to improve awareness and knowledge among oncology professionals and related healthcare providers.
